1. Genetic testing and the health care system

   • Oliver Schöffski

   OriginalPaper 25 February 2014 Pages: 73 - 76

2. Burden of illness imposed by severe sepsis in Germany

   • A. Schmid
   • H. Burchardi
   • H. Schneider

   Original papers 25 February 2014 Pages: 77 - 82

3. Risk-adjusted capitation funding models for chronic disease in Australia: alternatives to casemix funding

   • K. M. Antioch
   • M.K. Walsh

   Original papers 25 February 2014 Pages: 83 - 93

4. The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom

   • J. Bonastre
   • C. Le Pen
   • G. Berdeaux

   Original papers 25 February 2014 Pages: 94 - 102

5. Reputation, public information, and physician adoption of an innovation

   • J. G. Smythe

   Original papers 25 February 2014 Pages: 103 - 110

6. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine

   • Lukas Radbruch
   • K. Lehmann
   • G. Nuyts

   OriginalPaper 25 February 2014 Pages: 111 - 119

7. Association of time preference for health with age and disease severity

   • K. Stavem
   • I. S. Kristiansen
   • J. A. Olsen

   Original papers 25 February 2014 Pages: 120 - 124

8. Erratum to: Does health technology assessment benefit health services and politics?

   • H. Sigmund
   • F.B. Kristensen

   Erratum 25 February 2014 Pages: 124 - 124

9. Is EQ-5D a valid measure of HRQoL in patients with movement disorders?

   • S. Ghislandi
   • G. Apolone
   • I. Ghislandi

   Original papers 25 February 2014 Pages: 125 - 130

10. Developing a scoring system to quality assess economic evaluations

    • J. G. Gonzalez-Perez

    Original papers 25 February 2014 Pages: 131 - 136

11. Time for a change in drug licensing requirements?

    • Michael F. Drummond

    OriginalPaper 25 February 2014 Pages: 137 - 138

12. Commentary

    • J.-Matthias Graf von der Schulenburg

    In discussion 25 February 2014 Pages: 138 - 138

13. Commentary

    • Bengt Jönsson

    OriginalPaper 25 February 2014 Pages: 139 - 139

14. Time for a change in drug pricing : Going downstream

    • Gérard de Pouvourville

    In discussion 25 February 2014 Pages: 140 - 141

15. Drug licensing requirements are changing!

    • F. Lekkerkerker
    • F. Rutten

    OriginalPaper 25 February 2014 Pages: 141 - 142

16. A final comment

    • Michael F. Drummond

    OriginalPaper 25 February 2014 Pages: 142 - 142